Company intelligence / Profile preview

Cyted

United Kingdom

Ownership: Private
Development stage: Other

Overview

Cyted's EndoSign platform, featuring the minimally invasive capsule sponge device, has completed over 35,000 real-world NHS tests and is being validated in large prospective clinical studies in the US and UK for detecting Barrett's Esophagus and esophageal neoplasia. Their non-endoscopic diagnostics have demonstrated significant patient acceptability and enabled earlier disease detection in routine clinical practice.[1][4][5]

Therapeutic areas: OncologyGastroenterology
Modalities: DeviceBiologicArtificial intelligence
Industry: Pathology

Beyond the preview

Go deeper on Cyted.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyted.

Explore the full profile